Dr. Poznansky is an innovator whose work bridges academic discovery and clinical care. As a leader in the field of leukocyte migration and the modulation of leukocyte trafficking and function, he has linked discovery with the generation of new vaccine and immunotherapeutic approaches in infectious diseases, cancer and type 1 diabetes. Dr. Poznansky has gained recognition for establishing a new model for translational research that accelerates the process by which basic biological discoveries move towards products and technologies that improve patient care and treatment. Since 2009 he has served as the director of the translational Vaccine and Immunotherapy Center (VIC) at MGH, which is putting this model into practice. The goal of VIC is to enable efficient and rapid transition of promising technologies through preclinical development and into the clinical stage of development through technology spin outs, partnerships or out-licensing. He oversees the research work of a team of investigators, postdoctoral fellows and other trainees addressing key research questions regarding these new therapeutics and vaccines, and leads an operational team that facilitates the execution of business, regulatory, manufacturing, and other developmental tasks associated with the preclinical translation of these candidates. Relevant to this presentation, Dr. Poznansky is the PI of a DTRA funded study to develop a novel vaccine for Q fever and directs a program at VIC which has developed three new immunotherapeutic approaches to the treatment of cancer including ovarian cancer and mesothelioma. His team leaders, including Dr. Jeff Gelfand and Dr. Satoshi Kashiwagi, direct the development of a program to develop a novel, safe and efficacious near infra-red light based adjuvant for both infectious disease and cancer vaccines. Dr. Poznansky obtained his B.Sc. and his MD at the University of Edinburgh and his PhD in Medical Sciences at Cambridge University. He also served as a Resident in Clinical Immunology at the Addenbrooke’s Hospital in Cambridge, UK and a Captain in the Royal Army Medical Corps (V). He completed his post-doctoral research training in retrovirology at Harvard Medical School and the Dana Farber Cancer Institute. He completed his infectious diseases fellowship training at Imperial College and Harvard Medical School. He is the scientific founder of three biotech companies and serves as the Co-Director of the Medicine Innovation Program at MGH.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
